A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression

Journal of Gastrointestinal Oncology

Volumn 5, Issue 6, 2014, Pages E121-E124

  Panebianco, Michele ^a   Ragazzi, Moira ^a   Asensio, Nuria Maria ^a   Pagano, Maria ^a   Gnoni, Roberta ^a   Boni, Corrado ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Hepatocellular carcinoma (HCC); Panniculitis; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; HYDROXYUREA; SORAFENIB;

ABDOMINAL PAIN; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MALE; MEDICAL HISTORY; MYELOFIBROSIS; NECROTIZING ARTERITIS; PANNICULITIS; RADIOFREQUENCY ABLATION; VERY ELDERLY;

EID: 84995772485     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2014.079     Document Type: Article

References (13)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
3. Bruix J, Sherman M, Practice Guidelines Committee, et al. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47.
6. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
7. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
10. Faye E, Bondon-Guitton E, Olivier-Abbal P, et al. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013;69:1819-26.
11. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56.
12. Pragasam V, Verma R, Vasudevan B. Sorafenib and sunitinib: A dermatologist's perspective. Indian Dermatol Online J 2014;5:1-3.
13. Glinkov S, Krasnaliev I, Atanassova M, et al. Hepatocellular carcinoma associated with paraneoplastic erythema nodosum and polyarthritis. J Hepatol 2003;39:656-7.